The estimated Net Worth of Jake Bauer is at least $20.1 Million dollars as of 3 January 2020. Mr. Bauer owns over 10,000 units of MyoKardia stock worth over $13,484,929 and over the last 9 years he sold MYOK stock worth over $3,780,178. In addition, he makes $2,792,660 as Chief Business Officer at MyoKardia.
Sign up
Mr. Bauer MYOK stock SEC Form 4 insiders trading
Jake has made over 16 trades of the MyoKardia stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of MYOK stock worth $15,100 on 3 January 2020.
The largest trade he's ever made was selling 21,232 units of MyoKardia stock on 27 November 2019 worth over $1,386,662. On average, Jake trades about 3,514 units every 28 days since 2016. As of 3 January 2020 he still owns at least 59,957 units of MyoKardia stock.
You can see the complete history of Mr. Bauer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jake Bauer biography
Jake Bauer serves as Chief Business Officer of the Company. Prior to joining us, he was vice president, business operations and head of corporate development at Ablexis, LLC (“Ablexis”), a biotechnology company, from May 2011 to July 2014. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Prior to Ablexis, Mr. Bauer was a principal at Third Rock Ventures, where he identified, evaluated and developed new opportunities for investment, assisted with startup, corporate development and operations of portfolio companies, and negotiated financings from 2007 to 2011. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX Therapeutics Inc., Global Blood Therapeutics, Inc. and Zafgen, Inc., all biopharmaceutical companies. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma AG and the business development group at Endo Pharmaceuticals Inc. and was previously a management consultant at Putnam Associates. Mr. Bauer holds a B.Sc. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School. He currently serves on the Board of Directors of Phoenix Tissue Repair, Inc.
What is the salary of Jake Bauer?
As the Chief Business Officer of MyoKardia, the total compensation of Jake Bauer at MyoKardia is $2,792,660. There are 3 executives at MyoKardia getting paid more, with Tassos Gianakakos having the highest compensation of $10,223,600.
How old is Jake Bauer?
Jake Bauer is 41, he's been the Chief Business Officer of MyoKardia since 2018. There are 11 older and no younger executives at MyoKardia. The oldest executive at MyoKardia, Inc. is Mary Cranston, 72, who is the Independent Director.
What's Jake Bauer's mailing address?
Jake's mailing address filed with the SEC is C/O MYOKARDIA, INC., 1000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr und Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Mr. Bauer stock trades at MyoKardia
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,